XML 140 R121.htm IDEA: XBRL DOCUMENT v3.22.4

Contingencies and commitments (Janssen Biotech Inc v. Amgen Inc (Details)	Nov. 29, 2022 patent
Janssen Biotech Inc. Vs, Amgen Inc | Pending Litigation
Loss Contingencies [Line Items]
Number of patents allegedly infringed	2

X

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_LitigationCaseAxis=amgn_JanssenBiotechIncVsAmgenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: